These genotype-dependent profiles suggest the potential utility of integrated immunogenomic signatures in guiding personalised therapeutic strategies, particularly interventions targeting trogocytosis, immune checkpoint modulation, and HLA-G–mediated tolerance in lupus. The gene discussed is HLA-G; the disease is systemic lupus erythematosus.